Takeda completes sale of select non-core assets to cheplapharm

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescription products to cheplapharm for a total value of $562 million usd1. the portfolio includes 16 prescription pharmaceutical products sold predominantly in europe which is part of takeda's europe and canada business unit. this divestment agreement was first announced in september 2020. the divested port
TAK Ratings Summary
TAK Quant Ranking